Soleno Therapeutics Inc. (NASDAQ: SLNO) stock jumped 4.37% on Friday to $0.17 against a previous-day closing price of $0.17. With 1.09 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.03 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $0.1800 whereas the lowest price it dropped to was $0.1687. The 52-week range on SLNO shows that it touched its highest point at $1.02 and its lowest point at $0.13 during that stretch. It currently has a 1-year price target of $5.00. Beta for the stock currently stands at 0.27.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SLNO was down-trending over the past week, with a drop of -3.17%, but this was down by -10.29% over a month. Three-month performance dropped to -8.26% while six-month performance fell -50.36%. The stock lost -81.78% in the past year, while it has lost -57.49% so far this year. A look at the trailing 12-month EPS for SLNO yields -0.35 with Next year EPS estimates of -0.22. For the next quarter, that number is -0.06. This implies an EPS growth rate of 1.50% for this year and 12.50% for next year. EPS is expected to grow by 15.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 35.00%.
Float and Shares Shorts:
At present, 80.02 million SLNO shares are outstanding with a float of 47.91 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.71 million, which was 0.59% higher than short shares on Jun 14, 2022. In addition to Dr. Anish Bhatnagar M.D. as the firm’s Pres, CEO, COO & Director, Mr. James H. MacKaness serves as its Chief Financial Officer.
Through their ownership of 40.85% of SLNO’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 32.49% of SLNO, in contrast to 25.10% held by mutual funds. Shares owned by individuals account for 2.13%. As the largest shareholder in SLNO with 7.86% of the stake, Nantahala Capital Management LLC holds 9,436,512 shares worth 9,436,512. A second-largest stockholder of SLNO, AIGH Capital Management LLC, holds 6,800,000 shares, controlling over 5.66% of the firm’s shares. Birchview Capital LP is the third largest shareholder in SLNO, holding 3,676,899 shares or 3.06% stake. With a 1.00% stake in SLNO, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,201,052 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.62% of SLNO stock, is the second-largest Mutual Fund holder. It holds 749,100 shares valued at 0.14 million. Fidelity Extended Market Index Fu holds 0.22% of the stake in SLNO, owning 266,409 shares worth 49286.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SLNO since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SLNO analysts setting a high price target of $7.00 and a low target of $3.00, the average target price over the next 12 months is $5.00. Based on these targets, SLNO could surge 4017.65% to reach the target high and rise by 1664.71% to reach the target low. Reaching the average price target will result in a growth of 2841.18% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. SLNO will report FY 2022 earnings on 04/03/2023. Analysts have provided yearly estimates in a range of -$0.23 being high and -$0.28 being low. For SLNO, this leads to a yearly average estimate of -$0.26. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Soleno Therapeutics Inc. reported -$0.07 EPS against a consensus estimate of -$0.07. The surprise factor in the prior quarter was $0.04. Based on analyst estimates, the high estimate for the next quarter is -$0.05 and the low estimate is -$0.07. The average estimate for the next quarter is thus -$0.06.
Summary of Insider Activity:
Insiders traded SLNO stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 14 while that of sell transactions has risen to 7 over the past year. The total number of shares bought during that period was 13,909,938 while 211,998 shares were sold.